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(1.07%) respondents were diagnosed glaucoma. The average age in glaucoma group 
was 62.9 years and 43.3% were female compared to 51.9 years old with 49.3% female 
in non-glaucoma group. Glaucoma group reported more comorbidities, lower mean 
scores of PCS (39.1 vs. 47.1) and MCS (41.8 vs. 46.9), more patients visited health-
care providers (84.7% vs. 56.6%), ER (35.0% vs. 18.3%) and hospitalization (20.6% 
vs. 8.5%) in the past 6 months compared to non-glaucoma group. Also, glaucoma 
group reported 39.5% work/productivity loss (absenteeism and presenteeism) and 
42.1% impairment in daily activity compared to 21.8% and 23.3% in non-glaucoma 
group. All comparisons in QOL, MRU, and work/productivity loss between two 
groups were statistically signiﬁ cant at P < 0.05. CONCLUSIONS: From the China 
NHWS results, glaucoma patients suffer from impairment in quality of life, work/
productivity loss, more comorbidities and use of medical services. The ﬁ ndings indicate 
there is still an unmet medical need in glaucoma patients in China. 
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OBJECTIVES: Age-related macular degeneration (AMD) is the leading cause of blind-
ness and visual impairment. The prevalence increases proportionally to the number 
of aging population. Little is known about its economic consequences, therefore; this 
study is undertaken to determine economic outcomes associated with AMD in Thai-
land from the societal perspective. METHODS: Health resource utilization and direct 
medical costs were estimated based on a retrospective medical chart review of AMD 
patients at a University hospital during 2008–2009. We collected outpatient drug, 
intervention, medical visit and laboratory costs. Charges were converted to costs using 
a cost-to-charge ratio. Direct nonmedical costs and indirect costs were obtained from 
patient’s interview using a structured questionnaire at a University-afﬁ liated hospital. 
Patients were inquired about costs of transportation, additional food, medical device, 
house modiﬁ cation, and opportunity costs of care giver. Descriptive statistics were 
used. All costs were adjusted to year 2009 values. RESULTS: Twenty-two patient’s 
medical records were reviewed. Mean age was 67 years with 64% of male. The average 
number of medical visits was 11, while the cost for each outpatient visit was 233 USD. 
Drug costs accounted for 79% of total direct medical costs. The annual mean direct 
medical costs of AMD were USD2963. For direct nonmedical and indirect costs, 31 
patients were included. Mean age was 62 years with 39% of male. Four patients 
(12.9%) bought extra medical devices. A quarter of them (26%) needed a care giver 
to take care at home. On average, the amount of time care givers spent for caring 
patients was 11.3 hours/month. The mean annual direct nonmedical cost was USD168 
and USD85 for the opportunity costs of care giver. CONCLUSIONS: The economic 
consequences AMD were substantial. These estimates can be used as input parameters 
in a study evaluating the cost-effectiveness of interventions in patients with AMD. 
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OBJECTIVES: To estimate the direct and indirect economic costs of spectacle wear 
in Korea in patients with and without astigmatism. Intraocular lenses (IOLs) improve 
visual acuity after cataract surgery; however, patients must sometimes continue to 
wear spectacles. To date, there is a paucity of published information on the economic 
consequences of spectacle wear in Korea and the impact of wearing spectacles on an 
individual’s quality of life. METHODS: Participants to this cross-sectional survey met 
the following criteria: 1) Age > 45 years at the time of cataract surgery; 2) subject 
having had senile cataract surgery in both eyes; and 3) subject needing spectacles after 
cataract surgery. Patients completed a self-administered questionnaire on: demograph-
ics, spectacle and surgical costs, indirect costs and impact on daily activities. Lifetime 
spectacle costs were calculated from discounted average cost of spectacles, frequency 
of replacement and average life expectancy. The economic perspective was of the 
patient. RESULTS: A total of 150 patients were recruited from ﬁ ve eye hospitals in 
Korea. 41% of patients spend 30–60 minutes traveling to and from an appointment 
with 15% spend over 90 minutes. Indirect costs associated with traveling are also 
incurred by the relatives who accompany 67% of patients to their appointments. 
Patients with post cataract surgery astigmatism paid approximately twice as much for 
their spectacles as patients with no post surgery astigmatism (KRW431,531 and 
212,815, respectively.) The additional lifetime cost of spectacles for patients with 
postsurgery astigmatism is KRW2,065,152 which is higher than the associated addi-
tional out of pocket cost. CONCLUSIONS: Post surgery astigmatism can result in 
higher out of pocket (OOP) spectacle costs in Korea. These lifetime OOP costs are 
greater than the OOP costs associated with implanting premium IOLs. A better 
understanding of local spectacle costs has meaningful implications for patient decision-
making related to IOL choice. 
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OBJECTIVES: To evaluate the cost-effectiveness of a vision screening program for 
early detection of preschool children with amblyopia in Taipei City, Taiwan. 
METHODS: A decision analytic model was established to simulate the natural history 
of amblyopia in the context of Health Bureau of Taipei City Government. A societal 
perspective was undertaken to perform the cost-utility analysis and cost-beneﬁ t analy-
sis. Cumulative quality-adjusted life-years, lifetime beneﬁ ts, and lifetime costs for the 
following two strategies were compared: 1) A vision screening program was imple-
mented toward preschool children aged 4–6; 2) No vision screening program. Net 
beneﬁ ts and incremental cost-effectiveness ratio (ICER) were calculated to assess 
whether vision screening programs is cost-effective and cost-beneﬁ t. All costs and 
outcomes were discounted at an annual rate of 3%. One-way sensitivity analysis and 
probabilistic sensitivity analysis were performed to account for the uncertainty of the 
parameters. RESULTS: The model predicted the discounted average life-time QALYs 
were 29.2067 QALYs per child for strategy 1, and 29.2051 QALYs for strategy 2. 
The discounted average total lifetime costs were NT$723.9 and NT$593.6 per child 
for strategy 1 and strategy 2, respectively. ICER for the screening strategy was 
NT$80,932/QALY. The net social beneﬁ ts was NT$160.7 per child and the vision 
screening program for preschool children could potentially bring approximately 
NT$6,900,297 net beneﬁ t to the society. Results were most sensitive to the prevalence 
rate of amblyopic. The vision screening strategy was always preferred when a thresh-
old of willingness-to-pay for a QALY was >= NT$50,000. CONCLUSIONS: In 
comparison with no screening program, ICER for the vision screening program was 
found to be less than NT$555,760 (three times GDP per capita in 2007 in Taiwan). 
The vision screening program for preschool children aged 4–6 were cost-effective in 
Taipei City, Taiwan. 
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OBJECTIVES: To assess the cost-effectiveness of BTFC compared with DTFC using 
a payer perspective in Korea and Taiwan. METHODS: A 1-year decision analytic 
model simulated the effects on cohorts of open angle glaucoma patients in Korea and 
Taiwan from a payer perspective. Clinical effectiveness data (responder rates: percent-
age of patients that reach target intraocular pressure [IOP] of 18 mmHg) were derived 
from a non-inferiority phase III randomized clinical trial (RCT) of BTFC versus DTFC 
(Manni 2009). Comfort data were taken from a RCT comparing BTFC versus DTFC 
(Vold 2008). Compliance rates in relation to comfort (Barnebey 2000), risk of visual 
ﬁ eld defect (VFD) progression (Stewart 1993), and subsequent incremental medication 
utilization were estimated from literature. Medication costs were obtained from list 
prices. QALYs related to VFD were estimated from Korean-speciﬁ c and other Asian 
published data sources. Costs and effects were discounted at three percent and 
expressed in local currency. Cost-effectiveness threshold level was set at equivalent to 
the respective country’s gross domestic product (GDP) per capita. Sensitivity analyses 
were performed. RESULTS: The BTFC responder rate was 61% versus 59% for 
DTFC. Possibly due to the more physiological pH of the BTFC formulation, the 
discomfort rate was signiﬁ cantly better at 51% for BTFC and 83% for DTFC. BTFC 
economically dominated DTFC in Korea with 76,980 KRW savings and a gain of 0.02 
QALYs. In Taiwan, Azarga was highly cost-effective with an incremental cost of 800 
TWD, a QALY gain of 0.0259, and an incremental cost effectiveness ratio (ICER) of 
approximately 5% of GDP per capita. Sensitivity analyses demonstrated the robust-
ness of these ﬁ ndings. CONCLUSIONS: BTFC is non-inferior to DTFC with regards 
to IOP lowering potential, has a signiﬁ cantly better comfort proﬁ le, and is highly 
cost-effective in both Korea and Taiwan. 
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OBJECTIVES: Age-related macular degeneration (AMD) is the leading cause of blind-
ness and visual impairment which is associated with poor health-related quality of 
life. However, there remains a lack of good summary of pooled estimates of health 
utilities for AMD. This study aims to systematically review all studies estimating utility 
of AMD patients and meta-analyze them according to different visual acuity level. 
METHODS: A systematic search was performed using computerized databases includ-
ing Pubmed, EMBASE, CINAHL, Cochrane library, IPA, Psych Info, CEA registry 
